Journal
JOURNAL OF NANOBIOTECHNOLOGY
Volume 20, Issue 1, Pages -Publisher
BMC
DOI: 10.1186/s12951-022-01421-w
Keywords
Turmeric-derived nanoparticles; Ulcerative colitis; Nanotherapeutics; Oral administration; NF-kappa B pathway
Funding
- National Natural Science Foundation of China [82000523]
- Shaanxi Province's Science and Technology Innovation Team Program for Immune-related diseases [2021TD-38]
- Scientific Research Fund of National Health Commission-Major Health Science and Technology Program of Zhejiang Province [WKJ-ZJ-2205]
- Zhejiang Provincial Natural Science Foundation of China [LR22H160008]
- Young Talent Support Plan of Xi'an Jiaotong University, China [YX6J001]
Ask authors/readers for more resources
The study suggests that TDNPs 2 derived from turmeric are a novel and natural colon-targeting therapeutics that may prevent colitis and promote wound repair in colitis.
Background: Ulcerative colitis (UC) is an inflammatory bowel disease (IBD) characterized by diffuse inflammation of the colonic mucosa and a relapsing and remitting course. The current therapeutics are only modestly effective and carry risks for unacceptable adverse events, and thus more effective approaches to treat UC is clinically needed. Results: For this purpose, turmeric-derived nanoparticles with a specific population (TDNPs 2) were characterized, and their targeting ability and therapeutic effects against colitis were investigated systematically. The hydrodynamic size of TDNPs 2 was around 178 nm, and the zeta potential was negative (- 21.7 mV). Mass spectrometry identified TDNPs 2 containing high levels of lipids and proteins. Notably, curcumin, the bioactive constituent of turmeric, was evidenced in TDNPs 2. In lipopolysaccharide (LPS)-induced acute inflammation,TDNPs 2 showed excellent anti-inflammatory and antioxidant properties. In mice colitis models, we demonstrated that orally administrated ofTDNPs 2 could ameliorate mice colitis and accelerate colitis resolution via regulating the expression of the pro-inflammatory cytokines, including TNF-alpha, IL-6, and IL-1 beta, and antioxidant gene, HO-1. Results obtained from transgenic mice with NF-kappa B-RE-Luc indicated that TDNPs 2-mediated inactivation of the NF-kappa B pathway might partially contribute to the protective effect of these particles against colitis. Conclusion: Our results suggest that TDNPs 2 from edible turmeric represent a novel, natural colon-targeting therapeutics that may prevent colitis and promote wound repair in colitis while outperforming artificial nanoparticles in terms of low toxicity and ease of large-scale production.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available